v3.26.1
Leases - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2026
Dec. 31, 2025
Lessee, Lease, Description [Line Items]      
Lease not yet commenced   As of June 30, 2026, the Company has one lease which has not yet commenced or been recognized, since the facility is not yet available for the Company’s use.  
Fixed lease payments $ 1,300,000    
Operating lease right-of-use assets 35,798,000 $ 35,798,000 $ 26,130,000
Lease liability $ 41,459,000 $ 41,459,000  
Initial term of the lease 5 years 5 years  
Future minimum lease payments $ 79,909,000 $ 79,909,000  
Future minimum lease payments due in next 12 months 5,929,000 5,929,000  
Restricted Cash Held As Collateral      
Lessee, Lease, Description [Line Items]      
Restricted cash 1,300,000 $ 1,300,000  
New Operating Lease Facility      
Lessee, Lease, Description [Line Items]      
Operating lease description   In November 2021, the Company entered into a noncancelable operating lease for its current headquarters. The lease, as amended, commenced in January 2022 and expires in January 2034. A portion of the facility was subleased to Attovia Therapeutics, Inc. (“Attovia”), a related party, through March 2025.  
Lease for Manufacturing, Research and Office Space in Fremont, California      
Lessee, Lease, Description [Line Items]      
Operating lease right-of-use assets 10,800,000 $ 10,800,000  
Lease liability $ 10,700,000 $ 10,700,000  
Initial term of the lease 158 months 158 months  
Option to extend the lease, description   the Company has an option to extend the lease for one additional 5-year term.  
Option to extend the lease   true  
Extend term of the lease 5 years 5 years  
Maximum | Lease for Manufacturing, Research and Office Space in Fremont, California      
Lessee, Lease, Description [Line Items]      
Tenant improvement allowances receivable   $ 7,700,000